The global KRAS inhibitors market has experienced over 400% growth since the first approval in 2021, with four drugs now authorized for treating cancers with KRAS mutations.
BridgeBio Oncology merges with Helix Acquisition Corp. II in a $450M SPAC deal, securing $196M from trust account and $260M in PIPE financing led by Cormorant Asset Management.
BridgeBio Oncology Therapeutics has dosed the first patient in the ONKORAS-101 trial, studying BBO-8520, a novel treatment for KRASG12C non-small cell lung cancer. This marks a significant step in developing targeted therapies for this prevalent malignancy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.